# US 2012/0252879 A1 · Modulation of huntingtin expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252879 A1
- Document ID: US20120252879A1
- Status: Published application
- Kind: A1
- Application number: 13/395,188
- Filed: 2010-09-10
- Published: 2012-10-04
- Earliest claimed: 2009-09-11
- Assignees: Isis Pharmaceuticals, Inc.
- Inventors: Gene Hung; C. Frank Bennett; Susan M. Freier; Holly Kordasiewicz; Lisa Stanek; Don W. Cleveland; Seng H. Cheng; Lamya Shihabuddin
- Web page: https://patentgrep.com/patent/US20120252879A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 19/10: for osteoporosis
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 2310/11: Antisense
- C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2310/345: having at least two different backbone modifications
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.

## Claims

### Claim at position 1

-76. (canceled)

### Claim 77

A method for reducing the rate of progression of one or more symptoms of Huntington's disease in a subject in need thereof, comprising administering to the subject a compound comprising a modified oligonucleotide consisting of 12 to 30 linked nucleosides, wherein said compound specifically hybridizes to a nucleic acid sequence of the huntingtin gene.

### Claim 78 (depends on 77)

The method of claim 77, wherein said compound consists of a single-stranded modified oligonucleotide.

### Claim 79 (depends on 77)

The method of claim 77, wherein at least one internucleoside linkage of said compound is a modified internucleoside linkage.

### Claim 80 (depends on 79)

The method of claim 79, wherein each modified internucleoside linkage of said compound is a phosphorothioate internucleoside linkage.

### Claim 81 (depends on 77)

The method of claim 77, wherein at least one internucleoside linkage of said compound is a phosphodiester internucleoside linkage.

### Claim 82 (depends on 77)

The method of claim 77, wherein at least one nucleoside of said compound comprises a modified sugar.

### Claim 83 (depends on 82)

The method of claim 82, wherein at least one modified sugar is a bicyclic sugar.

### Claim 84 (depends on 82)

The method of claim 82, wherein at least one modified sugar comprises a 2′-O-methoxyethyl.

### Claim 85 (depends on 77)

The method of claim 77, wherein at least one nucleoside of said compound comprises a modified nucleobase.

### Claim 86 (depends on 85)

The method of claim 85, wherein the modified nucleobase is a 5-methylcytosine.

### Claim 87 (depends on 77)

The method of claim 77, wherein said compound comprises a chimeric oligonucleotide having a gap segment positioned between 5′ and 3′ wing segments.

### Claim 88 (depends on 87)

The method of claim 87, wherein the gap segment of the chimeric oligonucleotide consists of ten 2′-deoxynucleotides and each wing segment consists of five 2′-O-methoxyethyl-modified nucleotides.

### Claim 89 (depends on 87)

The method of claim 87, wherein the gap segment of the chimeric oligonucleotide consists of eight 2′-deoxynucleotides and each wing segment consists of five 2′-O-methoxyethyl-modified nucleotides.

### Claim 90 (depends on 88)

The method of claim 88, wherein each internucleoside linkage of said compound is a phosphorothioate internucleoside linkage.

### Claim 91 (depends on 89)

The method of claim 89, wherein each internucleoside linkage of said compound is a phosphorothioate internucleoside linkage.

### Claim 92 (depends on 88)

The method of claim 88, wherein each internucleoside linkage of the gap segment of said compound is a phosphorothioate internucleoside linkage and wherein at least one internucleoside linkage of each wing segment is a phosphodiester internucleoside linkage.

### Claim 93 (depends on 90)

The method of claim 90, wherein the nucleic acid sequence of said compound consists of SEQ ID NO:22 or SEQ ID NO:32.

### Claim 94 (depends on 91)

The method of claim 91, wherein the nucleic acid sequence of said compound consists of SEQ ID NO:33.

### Claim 95 (depends on 92)

The method of claim 92, wherein the nucleic acid sequence of said compound consists of SEQ ID NO:22 or SEQ ID NO:32.

### Claim 96 (depends on 77)

The method of claim 77, wherein said symptom is a physical symptom, a psychiatric symptom, or a peripheral symptom.

### Claim 97 (depends on 96)

The method of claim 96, wherein the physical symptom is restlessness, lack of coordination, unintentionally initiated motions, unintentionally completed motions, unsteady gait, chorea, rigidity, writhing motions, abnormal posturing, instability, abnormal facial expressions, difficulty chewing, difficulty swallowing, difficulty speaking, or seizure.

### Claim 98 (depends on 96)

The method of claim 96, wherein the psychiatric symptom is anxiety, depression, blunted affect, egocentrisms, aggression, compulsive behavior, irritability, or suicidal ideation.

### Claim 99 (depends on 96)

The method of claim 96, wherein the peripheral symptom is reduced brain mass.

### Claim 100 (depends on 98)

The method of claim 98, wherein the psychiatric symptom is anxiety.
